Approved Therapies

MET inhibitors (MET TKI):
- Capmatinib (TABRECTA®)
- Tepotinib (TEPMETKO®)
MET Antibody Drug Conjugate (MET ADC):
- Telisotuzumab vedotin-tllv (EMRELIS®) for MET overexpression by immunohistochemistry

View Other Treatments:

Second Opinion

Surgery

Radiation Therapy

Chemotherapy

Immunotherapy